文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19第一波疫情期间院内死亡率的变化:基于WHO临床特征描述方案UK的多中心前瞻性观察队列研究

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK.
PubMed 文献 · Lancet Respir Med · 2021-05-14
一句话结论英国247家医院第一波COVID-19住院患者28天院内死亡率从32.3%降至16.4%,调整后每7周死亡风险降低32%(OR 0.68),呼吸支持与激素使用解释22.2%的下降。

该多中心前瞻性观察队列研究通过WHO临床特征描述方案UK纳入2020年3月9日至8月2日英国247家急性医院63 972例≥18岁COVID-19住院患者。未调整28天院内死亡率从3月9日至4月26日的32.3%(95%CI 31.8-32.7)降至6月15日至8月2日的16.4%(95%CI 15.0-17.8),各年龄组、种族组、性别及有无合并症者均见下降。调整后每7周死亡风险降低32%(OR 0.68,95%CI 0.65-0.71);早期重症与合并症比例较高解释10.2%的下降,呼吸支持与激素使用变化解释22.2%(OR 0.95,95%CI 0.94-0.95)。作者认为剩余改善可能与社区行为、接种剂量及医院容量压力变化有关。

要点

  • 未调整28天院内死亡率从2020年3月9日至4月26日的32.3%(95%CI 31.8-32.7)降至6月15日至8月2日的16.4%(95%CI 15.0-17.8)。
  • 调整人口学、合并症和病情严重度后,每7周死亡风险降低32%(OR 0.68,95%CI 0.65-0.71)。
  • 第一波早期(3-4月)重症和合并症患者比例高于6-7月,解释10.2%的死亡率下降。
  • 呼吸支持(无创通气逐渐增加)和激素使用变化解释22.2%的死亡率下降,OR 0.95(95%CI 0.94-0.95)。
  • 死亡率下降见于所有年龄组、所有种族组、两性以及有无合并症的患者。

适用人群与场景

  • 2020年3月9日至8月2日英国英格兰、苏格兰和威尔士247家急性医院收治的≥18岁、有COVID-19临床体征和症状或RT-PCR确诊、假定社区获得性感染的住院患者。
  • 研究纳入63 972例合格患者,来自80 713例招募患者。

诊断标准与关键阈值

  • COVID-19诊断依据:临床体征和症状或RT-PCR检测确诊,且为假定社区获得性感染。
  • 主要结局为28天院内死亡,定义为观察周内入院患者中入院28天内死亡的比例,在所有有结局的患者中评估。

研究设计与关键结果

  • 研究类型:多中心前瞻性观察队列研究(ISRCTN66726260),纳入247家急性医院63 972例≥18岁COVID-19住院患者。
  • 主要终点:未调整28天院内死亡率从2020年3月9日至4月26日的32.3%(95%CI 31.8-32.7)降至6月15日至8月2日的16.4%(95%CI 15.0-17.8)。
  • 调整人口学、合并症和病情严重度后,每7周死亡风险降低32%(OR 0.68,95%CI 0.65-0.71)。
  • 第一波早期(3月和4月)重症和合并症患者比例高于6月和7月,解释10.2%的死亡率下降。
  • 呼吸支持变化(第一波期间无创通气使用逐渐增加)和激素使用解释22.2%的死亡率下降,OR 0.95(95%CI 0.94-0.95)。
  • 死亡率下降见于所有年龄组、所有种族组、两性以及有无合并症的患者。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察队列研究。
  • 采用三向分解中介分析(自然效应模型),调整人口学、合并症和病情严重度,量化呼吸支持水平和激素治疗等潜在中介因素。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,院内死亡率的下降部分由病例组合和病情严重度变化解释,呼吸支持和重症监护使用的差异与院内死亡率显著下降相关,可能部分反映临床知识的积累。
  • 作者认为,剩余的院内死亡率改善不能由上述因素解释,可能与社区行为、接种剂量和医院容量压力变化有关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Mortality rates in hospitalised patients with COVID-19 in the UK appeared to decline during the first wave of the pandemic. We aimed to quantify potential drivers of this change and identify groups of patients who remain at high risk of dying in hospital.

METHODS: In this multicentre prospective observational cohort study, the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK recruited a prospective cohort of patients with COVID-19 admitted to 247 acute hospitals in England, Scotland, and Wales during the first wave of the pandemic (between March 9 and Aug 2, 2020). We included all patients aged 18 years and older with clinical signs and symptoms of COVID-19 or confirmed COVID-19 (by RT-PCR test) from assumed community-acquired infection. We did a three-way decomposition mediation analysis using natural effects models to explore associations between week of admission and in-hospital mortality, adjusting for confounders (demographics, comorbidities, and severity of illness) and quantifying potential mediators (level of respiratory support and steroid treatment). The primary outcome was weekly in-hospital mortality at 28 days, defined as the proportion of patients who had died within 28 days of admission of all patients admitted in the observed week, and it was assessed in all patients with an outcome. This study is registered with the ISRCTN Registry, ISRCTN66726260.

FINDINGS: Between March 9, and Aug 2, 2020, we recruited 80 713 patients, of whom 63 972 were eligible and included in the study. Unadjusted weekly in-hospital mortality declined from 32·3% (95% CI 31·8-32·7) in March 9 to April 26, 2020, to 16·4% (15·0-17·8) in June 15 to Aug 2, 2020. Reductions in mortality were observed in all age groups, in all ethnic groups, for both sexes, and in patients with and without comorbidities. After adjustment, there was a 32% reduction in the risk of mortality per 7-week period (odds ratio [OR] 0·68 [95% CI 0·65-0·71]). The higher proportions of patients with severe disease and comorbidities earlier in the first wave (March and April) than in June and July accounted for 10·2% of this reduction. The use of respiratory support changed during the first wave, with gradually increased use of non-invasive ventilation over the first wave. Changes in respiratory support and use of steroids accounted for 22·2%, OR 0·95 (0·94-0·95) of the reduction in in-hospital mortality.

INTERPRETATION: The reduction in in-hospital mortality in patients with COVID-19 during the first wave in the UK was partly accounted for by changes in the case-mix and illness severity. A significant reduction in in-hospital mortality was associated with differences in respiratory support and critical care use, which could partly reflect accrual of clinical knowledge. The remaining improvement in in-hospital mortality is not explained by these factors, and could be associated with changes in community behaviour, inoculum dose, and hospital capacity strain.

FUNDING: National Institute for Health Research and the Medical Research Council.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021. PMID: 34000238. doi:10.1016/S2213-2600(21)00175-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。